South San Francisco, CA 12/3/10; Washington, DC 12/3/10—Fluidigm has filed an S-1 registration statement with the SEC for an IPO. Fluidigm provides microfluidic instrumentation and consumables for life science research, including gene expression, genotyping and digital PCR (see page 12). The number of shares and price range has not yet been determined. In 2009, the […]
Company Announcements As part of its new out-licensing strategy, Life Technologies announced in September the finalization of cell line license agreements to provide rights to its Chinese hamster ovary cell lines for the production of recombinant protein used as therapeutic agents and vaccines. In October, Teledyne Tekmar partnered with Analytical Sciences Group, which will be […]
In November, the Dow Jones Industrial Average reached a new two-year high of 11,406.84 following the US Federal Reserve’s $600 billion stimulus plan. Economic data continued to improve and included strong corporate earnings, rising consumer confidence and subdued inflation. On November 23, third-quarter US GDP growth was revised upward to 2.5%, compared with the previous […]
Washington, DC 11/15/10; Washington, DC 11/19/10—DNA sequencer firm Helicos BioSciences has been delisted from the NASDAQ stock exchange after withdrawing its appeal (see IBO 10/15/10). The stock now trades on the OTC Markets. Last month, the company received a delisting determination letter from NASDAQ due to its failure to comply with the minimum bid price […]
Momentum continued in the third quarter for sales growth at nine major analytical instrument and laboratory product companies. Driving sales were the rebound in industrial markets and continued growth in academic and applied markets, as well as weak year-over-year comparisons. However, for some companies, the European market remained lackluster. For the nine businesses whose quarterly […]
Sales of biosimilars, or follow-on biologics, could reach $10 billion by 2015, according to The Economist. US healthcare reform legislation signed into law earlier this year created an abbreviated FDA approval pathway for biosimilars. This month, the FDA held a two-day hearing about how to implement this pathway. Also this month, the European Medicine Agency […]
In the third quarter of 2010, revenues for IBO’s Laboratory Instrument Sales Index grew 8.9% to $5,240.26 million, including a loss of 0.8% from currency. Organic revenue growth was 9.6%, benefiting from increased demand and a weak year-over-year comparison. Asia remained the fastest-growing market. Europe was challenging. Operating profit improved 16.7% to $1,024.83 million, and […]
Two recent reports quantify the effect of the worldwide recession on corporate R&D spending. Both the European Union and Booz & Company found that R&D spending by the world’s largest publicly held R&D companies declined last year for the first time in many years. However, as both reports noted, R&D spending fell less than revenues […]
Company Announcements Revenue for Takara Bio’s Genetic Engineering Research unit declined 0.3% for the fiscal year ending March 31 to ¥16,689 million ($179.7 million) to make up 87% of Takara Bio sales. Operating income rose 8.7% to ¥4,151 million ($44.7 million) (see IBO 9/30/10). Sales of research reagents declined, partly due to the yen’s appreciation, […]
Strong third-quarter corporate earnings and future quantitative easing expectations boosted major US markets in October. The Dow Jones Industrial Average, S&P 500 and NASDAQ gained 3.1%, 3.7% and 5.9%, respectively. Unfortunately, higher profits have been spurred by restructuring initiatives, including reduced employment and restrained spending, defying support for economic growth. On October 29, the Commerce […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
